Sanofi-Aventis
Genzyme courting ‘white knight’ bid from Takeda
November 18, 2010Manufacturing and Production, Research and Development, Sales and Marketing Genzyme, Sanofi, Sanofi-Aventis, Takeda, pharma mergers
Genzyme is in talks with Takeda to secure a ‘white knight’ bid that would prevent Sanofi-Aventis from taking over the …
Genzyme again snubs suitor Sanofi
November 10, 2010Research and Development, Sales and Marketing Campath, Chris Viehbacher, Genzyme, Henri Termeer, Orphan Drugs, Plavix, Sanofi, Sanofi-Aventis, manufacturing compliance
Genzyme has once again snubbed Sanofi-Aventis as the French pharma firm continues its pursuit of the beleaguered biotech company. Henri …
Rep’s shotgun request misfires
October 28, 2010Sales and Marketing ABPI Code of Practice, PMCPCA, Sanofi-Aventis
Sanofi-Aventis has been found in breach of the ABPI Code over the conduct of one of its representatives in relation …
Sanofi moves teriflunomide into phase III MS trials
October 26, 2010Research and Development MS, Sanofi, Sanofi-Aventis, TERACLES, multiple sclerosis, relapsing multiple sclerosis, teriflunomide
Sanofi-Aventis is to begin the first phase III study of an oral drug as an add-on to standard therapy in …
Staff blockade Sanofi-Aventis facility in France
October 21, 2010Manufacturing and Production France, Sanofi, Sanofi-Aventis, job cuts, manufacturing and production
Workers at a Sanofi-Aventis manufacturing facility in Romainville, France, sealed off the gates of the plant to protest plans to …
Sanofi signs translational research deal with Harvard
October 18, 2010Research and Development Harvard, Sanofi-Aventis, academia, translational
Sanofi-Aventis is to collaborate on translational biomedical research with Harvard University in therapy areas such as cancer, diabetes and inflammation. …
Sanofi slashes US workforce
October 11, 2010Sales and Marketing Sanofi-Aventis, job cuts
Sanofi-Aventis is to cut a quarter of its workforce in the US – making 1,700 people redundant – as it …
Sanofi makes hostile offer for Genzyme
October 4, 2010Manufacturing and Production, Research and Development, Sales and Marketing Genzyme, Sanofi-Aventis
Sanofi-Aventis’ courtship dance around Genzyme has turned more aggressive with an offer – made over the heads of Genzyme’s board …
Sanofi signs $2.2bn CRO deal
October 1, 2010Research and Development CRO, Covance, Sanofi-Aventis
Sanofi-Aventis has signed a major deal to contract out a wide range of drug development and laboratory services as part …
Lixisenatide shaping up to rival Victoza
September 22, 2010Research and Development Lixisenatide, Sanofi-Aventis, diabetes
Data for Sanofi-Aventis’ injectable lixisenatide suggests it could rival Novo Nordisk’s drug Victoza.Lixisenatide is a once-daily GLP-1 receptor agonist, and …
Sanofi’s Multaq in pole position for AF market
September 6, 2010Sales and Marketing Multaq, Sanofi-Aventis, atrial fibrilation
New European Society of Cardiology guidelines on treating atrial fibrillation (AF) include a recommendation for Sanofi-Aventis’ Multaq. The endorsement is …
Genzyme available for ‘fair value’, says Termeer
September 2, 2010Research and Development, Sales and Marketing Genzyme, Sanofi-Aventis
Genzyme’s chief executive Henri Termeer has said his company could be for sale to Sanofi-Aventis if it offers a ‘fair …
Sanofi’s $18.5bn bid for Genzyme rejected
August 31, 2010Manufacturing and Production, Research and Development, Sales and Marketing Genzyme, Sanofi-Aventis
Sanofi-Aventis has gone public with its $18.5 billion offer for Genzyme after the US biotech’s board unanimously rejected the bid …
Multaq given limited approval from NICE
August 25, 2010Medical Communications, Sales and Marketing Multaq, NICE, Sanofi-Aventis, atrial, dronedarone
NICE has given a restricted approval to Sanofi-Aventis’s Multaq as a second line treatment for atrial fibrillation patients. The guidance …
Sanofi signs personalised medicine alliance
August 11, 2010Research and Development Sanofi-Aventis, Scripps Genomic Medicine, genomics
Sanofi-Aventis has signed a personalised medicine research alliance with US not-for-profit company Scripps Genomic Medicine. The company is part of …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
